文献速递浆细胞疾病造血干细胞移植与细胞治疗

卡非佐米方案在自体干细胞移植后复发多发性骨髓瘤患者中的疗效与安全性:ASPIRE与ENDEAVOR研究结果

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.
PubMed 文献 · Leukemia · 2017-04-25

本文为ASPIRE和ENDEAVOR两项3期试验的亚组分析,评估既往接受自体干细胞移植(ASCT)对卡非佐米方案疗效的影响。ASPIRE中446例、ENDEAVOR中538例有ASCT史,卡非佐米方案较非卡非佐米方案延长中位无进展生存期(PFS),总缓解率亦倾向卡非佐米方案,未发现新安全性信号。分析提示无论既往移植状态如何,卡非佐米方案可能改善PFS和缓解率,需进一步评估。

要点

  • ASPIRE有ASCT史者中位PFS:卡非佐米方案26.3个月 vs 非卡非佐米方案17.8个月(HR=0.68)。
  • ENDEAVOR有ASCT史者中位PFS:卡非佐米方案不可估计 vs 非卡非佐米方案10.2个月(HR=0.61)。
  • 无ASCT史者卡非佐米方案亦延长PFS,总缓解率倾向卡非佐米方案,未发现新安全性信号。

核心结论

  • 分析提示无论既往移植状态如何,卡非佐米为基础的治疗可能改善PFS和缓解率,需进一步评估。

研究设计与样本

  • ASPIRE和ENDEAVOR两项3期试验的亚组分析,按既往ASCT状态评估结局。
  • ASPIRE中446例、ENDEAVOR中538例患者有既往ASCT。

主要发现

  • 有ASCT史者中位PFS:ASPIRE卡非佐米方案26.3个月 vs 非卡非佐米方案17.8个月(HR=0.68);ENDEAVOR卡非佐米方案不可估计 vs 非卡非佐米方案10.2个月(HR=0.61)。
  • 仅一线治疗且含ASCT者中位PFS:ASPIRE卡非佐米方案29.7个月 vs 非卡非佐米方案17.8个月(HR=0.70);ENDEAVOR卡非佐米方案不可估计 vs 非卡非佐米方案11.2个月(HR=0.46)。
  • 无ASCT史者中位PFS:ASPIRE卡非佐米方案26.4个月 vs 非卡非佐米方案16.6个月(HR=0.76);ENDEAVOR卡非佐米方案17.7个月 vs 非卡非佐米方案8.5个月(HR=0.43)。
  • 总缓解率亦倾向卡非佐米为基础方案,未检测到新安全性信号。

关键数值与推荐

  • ASPIRE中卡非佐米方案为卡非佐米-来那度胺-地塞米松,对照为来那度胺-地塞米松。
  • ENDEAVOR中卡非佐米方案为卡非佐米-地塞米松,对照为硼替佐米-地塞米松。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibitor carfilzomib is approved for relapsed or refractory MM (RRMM). In phase 3 trials, carfilzomib-based regimens (ASPIRE, carfilzomib-lenalidomide-dexamethasone; ENDEAVOR, carfilzomib-dexamethasone) demonstrated superior progression-free survival (PFS) compared with standard therapies for RRMM (ASPIRE: lenalidomide-dexamethasone; ENDEAVOR, bortezomib-dexamethasone). This subgroup analysis of ASPIRE and ENDEAVOR evaluated outcomes according to prior ASCT status. In total, 446 patients in ASPIRE and 538 in ENDEAVOR had prior ASCT. Median PFS was longer for carfilzomib-based regimens vs non-carfilzomib-based regimens for patients with prior ASCT (ASPIRE: 26.3 vs 17.8 months (hazard ratio (HR)=0.68); ENDEAVOR: not estimable vs 10.2 months (HR=0.61)), those with one prior line of therapy that included ASCT (ASPIRE: 29.7 vs 17.8 months (HR=0.70); ENDEAVOR: not estimable vs 11.2 months (HR=0.46)), and those without prior ASCT (ASPIRE: 26.4 vs 16.6 months (HR=0.76); ENDEAVOR: 17.7 vs 8.5 months (HR=0.43)). Overall response rates also favored the carfilzomib-based regimens. No new safety signals were detected. This analysis suggests that carfilzomib-based treatment may lead to improvement in PFS and response rates regardless of prior transplant status. Further evaluation is warranted.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hari P, Mateos MV, Abonour R, et al. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. 2017. PMID: 28439109. doi:10.1038/leu.2017.122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。